MARKET

ZNTL

ZNTL

Zentalis Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.42
-0.99
-4.42%
After Hours: 21.05 -0.37 -1.73% 17:30 05/23 EDT
OPEN
22.52
PREV CLOSE
22.41
HIGH
22.76
LOW
20.82
VOLUME
604.39K
TURNOVER
0
52 WEEK HIGH
87.19
52 WEEK LOW
17.33
MARKET CAP
1.20B
P/E (TTM)
-5.5610
1D
5D
1M
3M
1Y
5Y
What Percentage Of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Do Insiders Own?
If you want to know who really controls Zentalis Pharmaceuticals, Inc. ( NASDAQ:ZNTL ), then you'll have to look at the...
Simply Wall St. · 2d ago
Zentalis Pharmaceuticals Announces Closing of Underwritten Offering of Common Stock
NEW YORK and SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways o...
GlobeNewswire · 5d ago
73 Biggest Movers From Yesterday
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday.
Benzinga · 6d ago
Zentalis Pharmaceuticals appoints Kimberly Blackwell as top boss
Clinical-stage biotech Zentalis Pharmaceuticals (NASDAQ:ZNTL) on Monday appointed board member Kimberly Blackwell as its CEO, replacing Anthony Sun. Before joining ZNTL, Blackwell was chief medical officer at Tempus, a privately
Seekingalpha · 05/16 14:25
Zentalis Pharmaceuticals prices $200M in stock offering
Zentalis Pharmaceuticals (NASDAQ:ZNTL) priced its underwritten offering of 10.3M shares at an offering price of $19.38/share for total gross proceeds of ~$200.2M. Offer is expected to close on May 18. Net proceeds to
Seekingalpha · 05/16 14:00
BRIEF-Zentalis Pharmaceuticals Announces Pricing Of Underwritten Offering Of Common Stock
reuters.com · 05/16 12:44
Zentalis Pharmaceuticals Prices 10,330,000 share common stock offering at $19.38/Share
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today
Benzinga · 05/16 11:30
BRIEF-Zentalis Pharma Appoints Kimberly Blackwell As Chief Executive Officer
reuters.com · 05/16 11:09
More
No Data
Learn about the latest financial forecast of ZNTL. Analyze the recent business situations of Zentalis Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

60.00%Strong Buy
40.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ZNTL stock price target is 82.40 with a high estimate of 120.00 and a low estimate of 51.00.
High120.00
Average82.40
Low51.00
Current 21.42
EPS
Actual
Estimate
-1.20-0.90-0.60-0.30
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 147
Institutional Holdings: 43.87M
% Owned: 78.45%
Shares Outstanding: 55.91M
TypeInstitutionsShares
Increased
54
2.06M
New
38
2.06M
Decreased
33
2.14M
Sold Out
14
208.31K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.48%
Pharmaceuticals & Medical Research
+0.70%
Key Executives
Non-Executive Chairman/Independent Director
David Johnson
Chief Executive Officer/Director
Kimberly Blackwell
Co-Founder/Chief Operating Officer
Kevin Bunker
Chief Financial Officer/Treasurer
Melissa Epperly
Senior Vice President
Dimitris Voliotis
Secretary
Alexis Pinto
Director
Cam Gallagher
Independent Director
Enoch Kariuki
Independent Director
Karan Takhar
No Data
No Data
About ZNTL
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidates, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors. Its other products include ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of non-Hodgkin’s lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.

Webull offers kinds of Zentalis Pharmaceuticals Inc stock information, including NASDAQ:ZNTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZNTL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZNTL stock methods without spending real money on the virtual paper trading platform.